Tanizaki, Junko

Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors

Kosaka, T., Tanizaki, J., Paranal, R. M., Endoh, H., Lydon, C., Capelletti, M., Repellin, C. E., Choi, J., Ogino, A., Calles, A., et al. (2017) · Cancer Research

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 131

KRAS Inhibitor Resistance in MET -Amplified KRAS G12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

Suzuki, S., Yonesaka, K., Teramura, T., Takehara, T., Kato, R., Sakai, H., Haratani, K., Tanizaki, J., Kawakami, H., Hayashi, H., et al. (2021) · Clinical Cancer Research

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 105

Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification

Tanizaki, J., Okamoto, I., Fumita, S., Okamoto, W., Nishio, K., & Nakagawa, K. (2011) · Oncogene

HER2/EGFR in Cancer ResearchPI3K/AKT/mTOR signaling in cancer

Cited by 70